Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive factors for the effect of the α1-D/A adrenoceptor antagonist naftopidil on subjective and objective criteria in patients with neurogenic lower urinary tract dysfunction.
Takeda M, Homma Y, Araki I, Kakizaki H, Yamanishi T, Yokota T, Gotoh M, Igawa Y, Seki N, Takei M, Yoshida M, Sugaya K, Nishizawa O; Japanese Naftopidil Neurogenic Lower Urinary Tract Dysfunction Study Group. Takeda M, et al. Among authors: nishizawa o. BJU Int. 2011 Jul;108(1):100-7. doi: 10.1111/j.1464-410X.2010.09682.x. Epub 2010 Nov 9. BJU Int. 2011. PMID: 21062392 Clinical Trial.
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Okitsu A, Hamada T, Kobayashi A, Kuroishi K. Yamaguchi O, et al. Among authors: nishizawa o. BJU Int. 2015 Oct;116(4):612-22. doi: 10.1111/bju.13068. Epub 2015 Apr 23. BJU Int. 2015. PMID: 25639296 Clinical Trial.
Phase III, randomised, double-blind, placebo-controlled study of the β3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder.
Yamaguchi O, Marui E, Kakizaki H, Homma Y, Igawa Y, Takeda M, Nishizawa O, Gotoh M, Yoshida M, Yokoyama O, Seki N, Ikeda Y, Ohkawa S. Yamaguchi O, et al. Among authors: nishizawa o. BJU Int. 2014 Jun;113(6):951-60. doi: 10.1111/bju.12649. Epub 2014 Mar 17. BJU Int. 2014. PMID: 24471907 Clinical Trial.
Defining overactive bladder as hypersensitivity.
Yamaguchi O, Honda K, Nomiya M, Shishido K, Kakizaki H, Tanaka H, Yamanishi T, Homma Y, Takeda M, Araki I, Obara K, Nishizawa O, Igawa Y, Goto M, Yokoyama O, Seki N, Takei M, Yoshida M. Yamaguchi O, et al. Among authors: nishizawa o. Neurourol Urodyn. 2007 Oct;26(6 Suppl):904-7. doi: 10.1002/nau.20482. Neurourol Urodyn. 2007. PMID: 17663416 Review.
299 results